Andrew Cittadine, Chief Operating Officer at Monopar Therapeutics (MNPR), bought 36,000 shares at $0.64 ($23K) on 2024-05-29, disclosed to the SEC on 2024-05-31.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.64 | 12,000 | $8K | 33.3% |
| 2 | $0.64 | 12,000 | $8K | 33.3% |
| 3 | $0.64 | 12,000 | $8K | 33.3% |
| Total | $0.64 avg | 36,000 | $23K | 100% |
| Filing → |
| MNPR | BUY | 2024-06-05 | $18K | — | Filing → |
| MNPR | BUY | 2022-11-16 | $50K | — | Filing → |